Building small pyramids

Building small pyramids

By Mike Ward Senior Editor

Big pharma's willingness to pay up for preclinical approaches to hot targets was again confirmed last week when Johnson & Johnson's Janssen Pharmaceutica N.V. unit established a drug discovery alliance with Astex Therapeutics Ltd. to develop inhibitors of fibroblast growth factor receptor and two other cancer targets selected by Janssen.

FGF receptor is a receptor tyrosine kinase that activates MAP kinase and the protein kinase B/Akt pathways. It has been linked to many diseases including multiple myeloma (MM) and breast, prostate, colon and bladder cancers. FGF receptor signaling has been linked to angiogenesis, which may

Read the full 1000 word article

How to gain access

Continue reading with a
two-week free trial.